Aligos Therapeutics (ALGS) Competitors $9.55 -0.23 (-2.35%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALGS vs. ASMB, OPTN, RLMD, IVVD, ANRO, COYA, GNLX, KPTI, TLSA, and ASRTShould you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Assembly Biosciences (ASMB), OptiNose (OPTN), Relmada Therapeutics (RLMD), Invivyd (IVVD), Alto Neuroscience (ANRO), Coya Therapeutics (COYA), Genelux (GNLX), Karyopharm Therapeutics (KPTI), Tiziana Life Sciences (TLSA), and Assertio (ASRT). These companies are all part of the "medical" sector. Aligos Therapeutics vs. Assembly Biosciences OptiNose Relmada Therapeutics Invivyd Alto Neuroscience Coya Therapeutics Genelux Karyopharm Therapeutics Tiziana Life Sciences Assertio Aligos Therapeutics (NASDAQ:ALGS) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends. Do insiders & institutionals believe in ALGS or ASMB? 60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 8.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 5.1% of Assembly Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend ALGS or ASMB? Aligos Therapeutics currently has a consensus target price of $75.00, indicating a potential upside of 685.34%. Assembly Biosciences has a consensus target price of $35.00, indicating a potential upside of 107.22%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aligos Therapeutics is more favorable than Assembly Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Assembly Biosciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media favor ALGS or ASMB? In the previous week, Assembly Biosciences had 25 more articles in the media than Aligos Therapeutics. MarketBeat recorded 28 mentions for Assembly Biosciences and 3 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.90 beat Assembly Biosciences' score of 0.10 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assembly Biosciences 2 Very Positive mention(s) 3 Positive mention(s) 15 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Neutral Which has stronger valuation & earnings, ALGS or ASMB? Assembly Biosciences has lower revenue, but higher earnings than Aligos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAligos Therapeutics$15.53M1.97-$87.68M-$20.50-0.47Assembly Biosciences$7.16M14.98-$61.23MN/AN/A Which has more risk and volatility, ALGS or ASMB? Aligos Therapeutics has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Is ALGS or ASMB more profitable? Assembly Biosciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,100.48%. Aligos Therapeutics' return on equity of -110.59% beat Assembly Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Aligos Therapeutics-1,100.48% -110.59% -63.90% Assembly Biosciences N/A -121.55%-43.06% Does the MarketBeat Community favor ALGS or ASMB? Assembly Biosciences received 217 more outperform votes than Aligos Therapeutics when rated by MarketBeat users. However, 65.00% of users gave Aligos Therapeutics an outperform vote while only 58.98% of users gave Assembly Biosciences an outperform vote. CompanyUnderperformOutperformAligos TherapeuticsOutperform Votes2665.00% Underperform Votes1435.00% Assembly BiosciencesOutperform Votes24358.98% Underperform Votes16941.02% SummaryAligos Therapeutics beats Assembly Biosciences on 9 of the 15 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALGS vs. The Competition Export to ExcelMetricAligos TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.56M$3.15B$5.33B$8.52BDividend YieldN/A1.77%5.07%4.13%P/E Ratio-0.4714.07125.0415.83Price / Sales1.97321.091,492.5992.35Price / CashN/A149.0539.5134.18Price / Book0.314.024.765.07Net Income-$87.68M-$42.25M$118.77M$225.38M7 Day Performance13.69%1.81%-0.38%0.06%1 Month Performance10.79%8.56%6.06%3.93%1 Year Performance-49.07%35.10%38.12%32.51% Aligos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALGSAligos Therapeutics4.6842 of 5 stars$9.55-2.4%$75.00+685.3%-49.1%$30.56M$15.53M-0.4790Upcoming EarningsASMBAssembly Biosciences4.4769 of 5 stars$17.71+5.4%$35.00+97.6%+58.7%$112.46M$7.16M0.00100Short Interest ↓OPTNOptiNose3.4218 of 5 stars$0.75-3.8%$4.00+433.3%-45.7%$113.09M$70.99M-2.08190Gap DownRLMDRelmada Therapeutics3.9834 of 5 stars$3.57-1.9%$7.50+110.1%+17.1%$109.83MN/A-1.2410Positive NewsIVVDInvivyd2.4939 of 5 stars$0.91-12.5%$11.33+1,149.7%-37.9%$108.21M$2.26M-0.50100Analyst ForecastNews CoverageANROAlto Neuroscience2.3493 of 5 stars$4.01-5.0%$24.40+508.5%N/A$107.81M$210,000.000.00N/ACOYACoya Therapeutics2.3564 of 5 stars$7.37-27.7%$16.67+126.1%+51.7%$107.74M$9.55M-10.106Analyst ForecastShort Interest ↑News CoverageHigh Trading VolumeGNLXGenelux2.8516 of 5 stars$3.09+4.4%$18.75+506.8%-79.7%$106.15M$8,000.00-3.2210Analyst ForecastShort Interest ↓News CoverageGap UpKPTIKaryopharm Therapeutics4.2653 of 5 stars$0.85-5.6%$5.00+490.0%+14.9%$105.61M$145.67M-0.72380Upcoming EarningsAnalyst ForecastShort Interest ↓News CoverageTLSATiziana Life Sciences1.451 of 5 stars$1.02+3.0%N/A+44.6%$105.15MN/A0.008News CoverageGap DownASRTAssertio2.1068 of 5 stars$1.10flat$3.44+212.5%-51.6%$104.87M$132.19M-0.2720 Related Companies and Tools Related Companies Assembly Biosciences Competitors OptiNose Competitors Relmada Therapeutics Competitors Invivyd Competitors Alto Neuroscience Competitors Coya Therapeutics Competitors Genelux Competitors Karyopharm Therapeutics Competitors Tiziana Life Sciences Competitors Assertio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALGS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
